Cardiff Oncology
CRDF | NASDAQ
$0.85
+$0.12 (+17.06%)
At close: Nov 16, 2026, 4:00 PM ET
$0.87
+$0.02 (+2.18%)
After-hours:
Nov 16, 2026, 7:58 PM ET
+17.06%
(1D)No price chart data available for 1D timeframe.
Rating
44.5
+1.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #404/1021 (Top 40%)
Key Statistics
Market Data
Market Cap $65.95M
1D Range
0.80 0.94
52W Range
0.73 3.21
Valuation (TTM)
PE -1.55
PB 2.35
EV/EBITDA -0.88
Valuation (NTM)
Forward PE N/A
Forward PEG 0.05
Price Target $2.00
Cash Flow
FCF Yield -60.6%
SBC Adj. FCF Yield -68.4%
SBC Impact -13.0%
Margins
Gross Margin -1579.8%
Operating Margin -7068.2%
FCF Margin -7145.3%
Growth (CAGR)
Revenue 3Y | 5Y 6.7% |
10.1%
Dil EPS 3Y | 5Y 24.4% |
8.2%
FCF 3Y | 5Y -6.8% |
-6.2%
Returns
ROA -103.4%
ROE -111.8%
ROIC -139.3%
Financial Health
Net Cash
$33.79M
Current Ratio 4.21
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and ...
Sector Healthcare
Industry Biotechnology
Employees 31
IPO Date Jul 27, 2004
Website www.cardiffoncology.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.12
Beat +13.02%
YoY:
+29.41% REV
$171K
Beat +110.00%
YoY:
+42.50%Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Hold
Price Target
$2.00
Upside
+135.29%
Buy (2)
Hold (3)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CRDF